Taken together, these studies indicate that CER-1236 alone displayed robust expansion in vivo and had potent anti-tumor effects against REC-1 targets in the presence or absence of ibrutinib, likely a result of baseline cell surface PS observed on REC-1 cells. Here, RAD1 is linked to neoplasm.